Janney Montgomery Scott LLC decreased its position in shares of Celgene Co. (NASDAQ:CELG) by 21.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 163,446 shares of the biopharmaceutical company’s stock after selling 45,805 shares during the period. Janney Montgomery Scott LLC’s holdings in Celgene were worth $15,419,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of the company. Oregon Public Employees Retirement Fund lifted its stake in Celgene by 9,691.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 16,495,997 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 16,327,522 shares during the last quarter. Norges Bank bought a new stake in shares of Celgene during the fourth quarter valued at approximately $484,390,000. Parnassus Investments CA raised its stake in shares of Celgene by 1,766.7% during the fourth quarter. Parnassus Investments CA now owns 2,800,000 shares of the biopharmaceutical company’s stock valued at $179,452,000 after acquiring an additional 2,650,000 shares in the last quarter. BlackRock Inc. raised its stake in shares of Celgene by 2.8% during the fourth quarter. BlackRock Inc. now owns 53,650,909 shares of the biopharmaceutical company’s stock valued at $3,438,486,000 after acquiring an additional 1,459,100 shares in the last quarter. Finally, Ellis Investment Partners LLC increased its holdings in Celgene by 9,377.1% during the first quarter. Ellis Investment Partners LLC now owns 1,327,458 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 1,313,451 shares during the period. Hedge funds and other institutional investors own 75.21% of the company’s stock.
Shares of Celgene stock traded down $0.49 during trading hours on Wednesday, reaching $93.85. The stock had a trading volume of 4,716,041 shares, compared to its average volume of 9,931,979. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $97.07. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.66 and a current ratio of 2.78. The company has a market cap of $66.19 billion, a P/E ratio of 12.33, a price-to-earnings-growth ratio of 0.44 and a beta of 1.68.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.10. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The firm had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.01 billion. During the same quarter in the prior year, the firm earned $2.05 EPS. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. Equities research analysts forecast that Celgene Co. will post 9.85 EPS for the current year.
Several brokerages recently issued reports on CELG. ValuEngine raised shares of Celgene from a “sell” rating to a “hold” rating in a report on Saturday, May 4th. BidaskClub raised shares of Celgene from a “buy” rating to a “strong-buy” rating in a report on Friday, May 24th. Barclays lowered shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price target on the stock. in a report on Friday, May 3rd. Mizuho set a $103.00 price target on shares of Celgene and gave the stock a “buy” rating in a report on Friday, April 5th. Finally, Cantor Fitzgerald lowered shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price objective on the stock. in a report on Friday, April 5th. Eighteen equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Celgene currently has a consensus rating of “Hold” and a consensus price target of $95.56.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: Why is Cost of Capital Important?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.